Throne Biotechnologies

Throne Biotechnologies, founded with a mission to revolutionize the treatment of autoimmune diseases, focuses on developing innovative stem cell therapies. Their flagship product, the Stem Cell Educator Therapy, aims to reset the immune system using cord blood stem cells (CB-SC) through a dialysis-like procedure. This approach targets the root causes of autoimmune conditions such as diabetes and alopecia. Throne Biotechnologies is committed to providing practical cures for these chronic illnesses, positioning itself at the forefront of regenerative medicine.

Notable figures associated with Throne Biotechnologies include Dr. Robin Ross, a renowned ophthalmologist who recently joined as Director of Ophthalmology. The company has achieved significant milestones, including receiving FDA approval for the Regenerative Medicine Advanced Therapy (RMAT) designation for their Stem Cell Educator Therapy in treating Type 1 Diabetes. Their pre-clinical studies have also shown promising results in ameliorating Graft-vs-Host Disease (GvHD). Throne Biotechnologies' pioneering work has had a substantial impact on the field of autoimmune disease treatment, offering hope for long-term solutions.